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. Thomsen HS, Morcos SK, Erley CM, et al., the Investigators in the
Abdominal Computed Tomography: Iomeron 400 versus Visipaque 320
Enhancement (ACTIVE) study. The ACTIVE trial: comparison of the
effects on renal function of iomeprol-400 and iodixanol 320 in patients
with chronic kidney disease undergoing abdominal computed tomogra-
phy. Invest Radiol 2008;43:170–8.
. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced
nephropathy in patients with chronic kidney disease undergoing com-
puted tomography: a double-blind comparison of iodixanol and iopam-
idol. Invest Radiol 2006;41:815–21.
eply
e would like to thank Drs. Cantor and Lim for their interest in
ur work (1). We disagree with their interpretation that the results
f our analysis favor iodixanol and believe that the correct
nterpretation of our study is that iodixanol may be superior to
ome low osmolar contrast media (LOCM), but there is no data to
uggest its superiority to other LOCM.
The authors point out 3 publications not included in the
eta-analysis. Of the 3 reports they mention, one (Nie et al. [2])
as published outside our pre-defined search window (1980
hrough November 30, 2008). Inclusion of the other 2 trials did
hange the summary statistic slightly, although the results re-
ained nonsignificant (risk ratio [RR]: 0.74, 95% confidence
nterval [CI]: 0.53 to 1.02, p 0.069, p for heterogeneity 0.03).
nclusion of all 3 trials shifts the results in favor of iodixanol
ompared with the pool of LOCM (RR: 0.70; 95% CI: 0.50 to
.97; p  0.03, p for heterogeneity  0.02). However, the
omparison of iodixanol with various types of LOCM remains
nchanged: iodixanol causes less contrast-induced acute kidney
njury (CI-AKI) compared with ioxaglate (3 studies; RR: 0.58;
5% CI: 0.37 to 0.92; p  0.02) and iohexol (2 studies; RR: 0.19;
5% CI: 0.07 to 0.56; p  0.002) but has no relative difference in
I-AKI compared with iopromide (5 studies; RR: 0.731; 95% CI:
.36 to 1.48; p  0.38), iopamidol (4 studies; RR: 0.97; 95%
I: 0.58 to 1.58; p  0.89), and ioversol (2 studies; RR: 0.62;
5% CI: 0.22 to 1.74; p 0.37). This re-emphasizes the point that
odixanol has similar renal safety compared with some contrast
edia and may be safer with respect to renal toxicity when
ompared with other LOCM.
The authors also indicate that the included studies varied in
emographic and clinical parameters. Indeed, this is a limitation of
ll meta-analyses, but to some extent this makes the results more
eneralizable. With regard to the concern that some randomized
rials only checked serum creatinine a single time after 48 h, it is
orth reiterating that serum creatinine tends to peak 48 to 72 hfter contrast exposure. Although more frequent serum creatinine
hecks may result in a higher observed incidence of CI-AKI in
oth the iodixanol and the LOCM groups, it is not clear this
ould change the overall conclusion of each study.
Contrary to the letter authors’ suggestion, the IMPACT
IMpaired PAtients undergoing Computed Tomography) trial
ppropriately fulfilled the criteria for inclusion in our analysis (3).
urther, as demonstrated by our influence analysis, the exclusion of
single trial would not change the overall result of the meta-
nalysis.
We share the letter authors’ advocacy for quality patient care
nd quality clinical design. Further investigative trials comparing
pecific contrast media would continue to illuminate the most
ptimal ways to minimize CI-AKI. In light of conflicting data and
ngoing debate, the proposed superior safety of iodixanol com-
ared with all types of LOCM is less well established than when
he 2007 American College of Cardiology/American Heart Asso-
iation guidelines provided a Class IA recommendation for its use
n the setting of unstable angina or non–ST-segment elevation
yocardial infarction and renal insufficiency (4).
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